Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
#VisualAbstract: Plozasiran reduces serum triglyceride levels in ...
FDA Accepts Arrowhead’s New Drug Application for Plozasiran Treatment
Arrowhead Pharma Gets FDA Approval for Plozasiran in Chylomicronemia ...
Arrowhead Pharmaceuticals Launches Expanded Access Program for Plozasiran
Arrowhead's Rare Disease Drug Plozasiran Gets FDA Review After Strong ...
Arrowhead Pharma gets FDA Breakthrough Therapy nod for plozasiran ...
FDA 授予 Arrowhead 公司的 plozasiran 突破性疗法认定 - 知乎
Plozasiran secures FDA breakthrough status for FCS, closing gap with ...
REDEMPLO- plozasiran injection, solution
Plozasiran vs Olezarsen: Two RNA Paths to ApoC-III Control
Arrowhead Pharmaceuticals presents plozasiran and data at AHA 2023
Plozasiran Reduces Triglycerides, ApoC3 in Phase 2b SHASTA-2 Trial ...
FDA grants breakthrough therapy status to Arrowhead’s plozasiran
Arrowhead Pharmaceuticals: RNA interference Medication Plozasiran ...
Arrowhead Pharmaceuticals Sells Rights to Sanofi for Plozasiran in ...
plozasiran (ARO-APOC3) / Arrowhead
Arrowhead Pharmaceuticals' Plozasiran NDA Acceptance: A Breakthrough ...
Plozasiran Receives FDA Approval to Reduce Triglycerides in Adults with ...
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO ...
FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for ...
FDA Label for Redemplo Injection, Solution Subcutaneous - Indications ...
Arrowhead Pharmaceuticals: Hoping Something Sticks (NASDAQ:ARWR ...
Full article: Assessing the clinical potential of plozasiran, an APOC3 ...
Arrowhead Pharmaceuticals Secures FDA Approval for REDEMPLO ...
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection ...
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation ...
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE ...
Arrowhead Pharmaceuticals Receives the US FDA’s Approval for Redemplo ...
Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to ...
Arrowhead Pharmaceuticals Receives FDA Approval for REDEMPLO ...
Плозасиран — МНН (Международное непатентованное наименование)
每三月皮下注射一次！FCS新药plozasiran里的invAb作用大揭秘 - 芜湖华仁科技有限公司
Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation ...
FinancialContent - Arrowhead Pharmaceuticals Receives FDA Breakthrough ...
FDA approves Redemplo (plozasiran) as an adjunct to diet to reduce ...
箭頭製藥瞄準2025年推出plozasiran，手握11億美元現金與臨床管道動能！-CMoney 研究員 | CMoney投資網誌
Arrowhead Pharmaceuticals: Navigating a Narrowing Loss and a Pivotal ...
Arrowhead Pharmaceuticals получает статус Breakthrough Therapy ...
药物研发商Arrowhead Pharmaceuticals公布Plozasiran在家族性乳糜微粒血症综合征患者中开展的关键性三期 ...
Triglyceride-Lowering Drug Gets FDA Nod for Rare Genetic Disorder ...
-p-1080.png)
